SIDE-BY-SIDE COMPARISON

CompareRecursionvsAtomwise

Review features, pricing signals, strengths, and trade-offs before choosing.

Generated from current catalog profiles Catalog profile signals Use-case comparison
AI Drug Discovery & Molecule Design Software

Recursion

SF 8.1

AI biotech with cellular imaging and automation

Contact sales

Quick decision guide

Choose based on your workflow

Recursion may fit better if...

  • Multi Omics
  • Lab Integration
  • Partner Workflows

Atomwise may fit better if...

  • Molecule Design
  • Protein Modeling
  • Knowledge Graph

Overview

How each tool is described

Recursion

Recursion is an AI drug discovery company that uses cellular imaging, automation, and machine learning to identify and validate new drug candidates. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

The clearest fit for Recursion is pharma collaborators and internal pipeline programs, with the platform leaning into phenomics platform with multimodal data. Limitations are real: direct buyer access is limited to partnerships. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should confirm validation depth, support coverage, and rollout plan before signing.

View full Recursion profile

Atomwise

Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.


• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.

• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.

• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.

• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.


Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.

View full Atomwise profile

Side-by-side

Key differences

Criteria
AI Drug Discovery & Molecule Design SoftwareRecursion
AI Drug Discovery & Molecule Design SoftwareAtomwise
Best for
AI Drug Discovery & Molecule Design Software
AI Drug Discovery & Molecule Design Software
Score
8.1/10
7.9/10
Pricing
Contact sales
Contact sales
Category / audience
AI Healthcare & Medical Software › AI Drug Discovery & Molecule Design Software
AI Healthcare & Medical Software › AI Drug Discovery & Molecule Design Software

OVERLAP

Where Recursion and Atomwise are similar

Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.

3 capabilities5 workflows

Shared capabilities

Capability overlap

  • Virtual ScreeningScreens compound libraries against targets
  • Literature IntelligenceMines biomedical literature for relevant evidence
  • Target DiscoveryIdentifies potential drug targets from biological data

Shared workflows

Workflow overlap

  • Run virtual screens against targetsRun virtual screening across large compound libraries.
  • Collaborate with pharma partnersCollaborate with pharma partners on discovery programs.
  • Identify drug targets from biology dataSurface potential drug targets from biological data signals.

Feature check

Side-by-side feature check

Feature
Recursion
Atomwise
Multi OmicsIntegrates genomic and other omics data sources
-
Lab IntegrationConnects discovery insights with wet-lab workflows
-
Partner WorkflowsWorkflows for pharma partner collaborations
-
Molecule DesignGenerates and ranks potential small-molecule drug candidates
-
Protein ModelingPredicts and designs protein structures using AI
-
Knowledge GraphConnects biological and chemical data to uncover research insights
-
9 capabilities compared.6 differentiating rows are shown first.

The trade-offs

Pros & cons of each tool

Trade-offs

Recursion

Pros
  • Phenomics platform with massive multimodal data
  • Active pharma collaborations and internal pipeline
  • Public company with transparent disclosures
Cons
  • Direct buyer access remains limited to partnerships
  • Drug development cycles take many years
  • Recursion brand evolves with Exscientia integration
Trade-offs

Atomwise

Pros
  • AtomNet-powered structure-based drug discovery
  • Partnerships across multiple therapeutic areas
  • Strong focus on small-molecule virtual screening
Cons
  • Available through partnerships rather than self-service
  • Drug candidates require further clinical development
  • Narrower focus than end-to-end drug discovery platforms

Final verdict

Best fit depends on your workflow

Catalog verdict · low confidence

Current catalog data shows meaningful overlap between Recursion and Atomwise. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.

Shared catalog overlap

Recursion and Atomwise share 8 catalog signals, so the decision should focus on fit rather than broad capability alone.

Differentiators available

Recursion has 4 visible decision signals and Atomwise has 4.

Score signal

Recursion has the higher SoftFinders Score in the current catalog data.

TRY THEM YOURSELF

See which one fits your workflow

Both tools have their strengths, the best way to decide is to spend a few minutes inside each.